Neurelis Wins 2023 Pm360 Pharma Choice Multichannel Gold Award For 'Give Seizures The Sprayer' Marketing Campaign

● 'Give Seizures the Sprayer’, marketing campaign led by Beth Henriksen, Director of Marketing, Neurelis, Inc., wins the 2023 PM360 Pharma Choice Multichannel Gold Award

SAN DIEGO, CA  — March 2, 2023   — Neurelis, Inc. is proud to announce the ‘Give Seizures the Sprayer’ marketing campaign for VALTOCO® (diazepam nasal spray) CIV has won a 2023 PM360 Pharma Choice Multichannel Gold Award. PM360, a leading health and life sciences marketing industry trade magazine, established the Pharma Choice Awards to honor the year's best creative campaigns and marketing initiatives from the life sciences industry. Based on popular vote from the publication's readers, voters are asked to assess submissions based on content, format, imagination, influence on the industry, audience impact, and overall quality. More than 8,500 votes were cast for the 13th Annual PM360 Pharma Choice Awards.

“This award is an incredible honor, notably as it is voted upon by peers and fellow marketers. We all understand the work that goes into campaign development and the goal to be both differentiated and authentic,” said Beth Henriksen, Director of Marketing, Neurelis. “The campaign was inspired by the shared frustration people with epilepsy and their care partners experience when their daily lives are disrupted by seizure clusters. We channeled that energy into this campaign to spark conversation and bring awareness to VALTOCO as a treatment option.”

Created in collaboration with Fingerpaint Marketing, a full-service advertising agency that specializes in creating analytics-enabled integrated solutions for biopharma, the ‘Give Seizures the Sprayer’ campaign reflects the relief and spirit VALTOCO evokes in people with epilepsy who experience seizure clusters and their care partners. With the goal of empowering people to stand up to seizure clusters, the messaging shined through.

“At Neurelis, we partner with those impacted by epilepsy to foster confidence in a rescue therapy that can help get them back to their daily activities,” said Founder and CEO of Neurelis, Craig Chambliss. “Empowering people with epilepsy to manage their seizure clusters and have a better quality of life is at the heart of everything we do.”

VALTOCO is the most prescribed FDA-approved product for short-term treatment of seizure clusters in adult and pediatric patients 6 years of age and older. VALTOCO was approved by the U.S. Food and Drug Administration (FDA) on Jan. 10, 2020.

About Neurelis

Neurelis, Inc., is a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need. In 2020, the FDA approved Neurelis’ VALTOCO® (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from an individual’s usual seizure pattern in adult and pediatric patients 6 years of age and older. VALTOCO is a proprietary formulation of diazepam incorporating the science of INTRAVAIL®. Intravail’s transmucosal absorption enhancement technology enables the noninvasive delivery of a broad range of protein, peptide and small-molecule drugs. In its approval of VALTOCO, the U.S. Food and Drug Administration also granted Neurelis Orphan Drug Exclusivity and recognized VALTOCO’s intranasal route of administration as a clinically superior contribution to patient care over the previously approved standard-of-care treatment (a rectal gel formulation of diazepam). For more information on VALTOCO, please visit http://www.valtoco.com/. In addition to VALTOCO, Neurelis is developing NRL-4 as a noninvasive rescue therapy to address the escalation of acute agitation symptoms associated with schizophrenia and bipolar 1 mania in adults. In addition, Neurelis is developing NRL-1049 (previously known as BA-1049), an investigational, pre-clinical stage small molecule Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMS), a rare disorder of the central nervous system (CNS). For more information on Neurelis, please visit http://www.neurelis.com/. For the latest scientific information on VALTOCO, please visit http://www.neurelismedicalaffairs.com/.